September S&P 500 E-Mini futures (ESU25) are trending up +0.24% this morning as investors digested U.S. President Donald ...

Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising ...

The S&P 500 declined 0.5% on Tuesday, Aug. 5, 2025, as a key gauge of the services sector showed a slump in July and trade ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

IBD 50 and IBD Big Cap 20 name Palantir Technologies PLTR surged around 7% and reached a record high on the stock market ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial ...

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic ...

Key Takeaways U.S. equities declined at midday following a soft services industry report and President Donald Trump's ...

Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.

U.S. stock futures are pointing higher after indexes surged Monday to rebound from last week's selloff. Nasdaq futures are 0.4% higher after the tech-heavy index gained 2% in the prior session, while ...

CRISPR Therapeutics (CRSP) stock falls as company's Q2 results miss consensus amid focus on its Cagevy gene therapy developed with Vertex Pharma (VRTX). Read more here.